Zimmer Partners Lp increased Oge Energy Corp (OGE) stake by 257.14% reported in 2017Q4 SEC filing. Zimmer Partners Lp acquired 450,000 shares as Oge Energy Corp (OGE)’s stock declined 2.27%. The Zimmer Partners Lp holds 625,000 shares with $20.57 million value, up from 175,000 last quarter. Oge Energy Corp now has $6.57B valuation. The stock increased 0.34% or $0.11 during the last trading session, reaching $32.91. About 1.48 million shares traded. OGE Energy Corp. (NYSE:OGE) has declined 8.90% since April 27, 2017 and is downtrending. It has underperformed by 20.45% the S&P500.
OGE Energy Corp. (NYSE:OGE) Ratings Coverage
Among 11 analysts covering OGE Energy (NYSE:OGE), 3 have Buy rating, 0 Sell and 8 Hold. Therefore 27% are positive. OGE Energy had 23 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of OGE Energy Corp. (NYSE:OGE) has “Hold” rating given on Thursday, December 3 by Wunderlich. The stock of OGE Energy Corp. (NYSE:OGE) earned “Hold” rating by Bank of America on Thursday, January 18. KeyBanc Capital Markets maintained the stock with “Hold” rating in Wednesday, October 18 report. The stock has “Hold” rating by Jefferies on Friday, July 21. Bank of America initiated OGE Energy Corp. (NYSE:OGE) rating on Tuesday, October 24. Bank of America has “Sell” rating and $37.0 target. Goldman Sachs upgraded it to “Buy” rating and $38.0 target in Wednesday, January 10 report. The firm has “Hold” rating by Wunderlich given on Friday, November 6. Edward Jones downgraded the stock to “Hold” rating in Wednesday, December 27 report. The stock of OGE Energy Corp. (NYSE:OGE) has “Hold” rating given on Thursday, July 20 by Goldman Sachs. Bank of America upgraded OGE Energy Corp. (NYSE:OGE) on Friday, February 23 to “Buy” rating.
Zimmer Partners Lp decreased Equinix Inc (NASDAQ:EQIX) stake by 82,435 shares to 393,665 valued at $178.42M in 2017Q4. It also reduced Comcast Corp New (NASDAQ:CMCSA) stake by 462,500 shares and now owns 1.56 million shares. Southern Co (NYSE:SO) was reduced too.
Since February 26, 2018, it had 2 insider buys, and 0 sales for $63,162 activity. Shares for $59,934 were bought by Clarke Peter D.. The insider WALWORTH CHARLES B bought $3,228.
Investors sentiment increased to 1.09 in Q4 2017. Its up 0.09, from 1 in 2017Q3. It is positive, as 28 investors sold OGE shares while 110 reduced holdings. 50 funds opened positions while 100 raised stakes. 121.48 million shares or 1.46% less from 123.28 million shares in 2017Q3 were reported. Motley Fool Wealth Ltd Co invested 0.02% in OGE Energy Corp. (NYSE:OGE). Amundi Pioneer Asset Management owns 0.07% invested in OGE Energy Corp. (NYSE:OGE) for 1.44 million shares. Cranbrook Wealth Management Ltd Co invested 0% in OGE Energy Corp. (NYSE:OGE). Mariner Wealth Advisors Limited Co holds 52,951 shares or 0.07% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0.01% of its portfolio in OGE Energy Corp. (NYSE:OGE). Assetmark has invested 0% in OGE Energy Corp. (NYSE:OGE). Bartlett & Limited Liability has 2,674 shares. California State Teachers Retirement Systems invested in 0.02% or 368,431 shares. Webster Savings Bank N A owns 1,300 shares for 0.01% of their portfolio. Advisory Service Lc invested in 0% or 1,136 shares. Endurance Wealth Mngmt Incorporated reported 0% of its portfolio in OGE Energy Corp. (NYSE:OGE). Ameriprise Financial has invested 0.01% in OGE Energy Corp. (NYSE:OGE). 216,707 were accumulated by Bb&T Corp. Southernsun Asset Ltd Limited Liability Company accumulated 2.41 million shares. Tompkins Financial reported 900 shares stake.
Investors sentiment increased to 1.62 in 2017 Q4. Its up 0.91, from 0.71 in 2017Q3. It improved, as 3 investors sold OncoMed Pharmaceuticals, Inc. shares while 18 reduced holdings. 15 funds opened positions while 19 raised stakes. 19.21 million shares or 47.57% more from 13.02 million shares in 2017Q3 were reported. Deutsche Bancorp Ag holds 2,984 shares or 0% of its portfolio. Primecap Mgmt Ca owns 5.57 million shares. Drw Securities Ltd Liability Corp reported 13,740 shares. Alyeska Investment Gru Lp, a Illinois-based fund reported 521,883 shares. Connor Clark Lunn Investment Mgmt Ltd has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Jacobs Levy Equity Mgmt Inc reported 0% stake. Fny Managed Accounts Limited Liability Company reported 500 shares. Art Advsrs Ltd Co has 27,052 shares. 28,686 were accumulated by Wells Fargo & Co Mn. Meeder Asset Management owns 1,096 shares. 38,000 were accumulated by Nj State Employees Deferred Compensation Plan. Endurant Capital Management Limited Partnership owns 139,100 shares. Bluecrest Cap Mngmt holds 32,382 shares. 59,017 are owned by Northern Trust. Disciplined Growth Investors Mn has 314,465 shares for 0.03% of their portfolio.
Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on May, 14. They expect $-0.24 EPS, up 60.66% or $0.37 from last year’s $-0.61 per share. After $0.25 actual EPS reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -196.00% negative EPS growth.
Alicia Hager; that is an insider in Oncomed Pharmaceuticals Inc who is the last to sell shares in the corporation for which she is presently the SVP & General Counsel. She lately made a sale of 4,051 shares of the company, worth total $10,848 U.S Dollars, that is a price for each share of close to $2.7. At present, Alicia Hager has ownership of 54,596 shares or 0.14% of the company’s market capitalization. The date was April 26, 2018 when Alicia finished the transaction, and it was made public in a Form 4 with the SEC, freely obtainable on this website.
OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $115.54 million. The company??s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.
Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. OncoMed Pharmaceuticals has $40 highest and $3.0 lowest target. $7.63’s average target is 152.65% above currents $3.02 stock price. OncoMed Pharmaceuticals had 21 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, December 20 by SunTrust. Jefferies initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Wednesday, September 9. Jefferies has “Buy” rating and $32 target. The stock has “Buy” rating by Cantor Fitzgerald on Monday, April 18. The firm has “Buy” rating by Jefferies given on Tuesday, September 26. BMO Capital Markets initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Tuesday, April 12. BMO Capital Markets has “Outperform” rating and $20 target. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. On Tuesday, March 20 the stock rating was maintained by H.C. Wainwright with “Hold”. BMO Capital Markets downgraded the shares of OMED in report on Tuesday, April 11 to “Market Perform” rating. Mizuho maintained the stock with “Buy” rating in Tuesday, January 26 report. The company was initiated on Friday, December 4 by Wells Fargo.
The stock increased 3.60% or $0.11 during the last trading session, reaching $3.02. About 130,268 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 65.75% since April 27, 2017 and is downtrending. It has underperformed by 77.30% the S&P500.